FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to immunology. Disclosed is a non-competitive neuregulin (NRG) allosteric antibody against human HER3 and a fragment thereof, as well as a coding nucleic acid, a vector, a host cell, a pharmaceutical composition and a method of treating cancer.
EFFECT: present invention can find further application in diagnostics and therapy.
15 cl, 13 dwg, 2 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MUTANT FULLY HUMANISED ANTIBODY AGAINST HER2 AND ENCODING GENE AND THEIR APPLICATION | 2015 |
|
RU2639531C1 |
| COMPOSITION OF HER2 ANTIBODIES | 2005 |
|
RU2361880C2 |
| NEW BINDING MOLECULES WITH ANTI-TUMOUR ACTIVITY | 2013 |
|
RU2627185C1 |
| INTRODUCTION OF FIXED DOSES OF HER-ANTIBODIES | 2005 |
|
RU2438705C2 |
| CANCER-RELATED IMMUNOSUPPRESSION INHIBITOR | 2018 |
|
RU2805232C2 |
| COMPOSITION CONTAINING ANTIBODY BINDING TO DOMAIN II OF HER2, AND ITS ACIDIC VERSIONS | 2009 |
|
RU2543664C2 |
| THERAPY OF MALIGNANT TUMOR, RESISTANT TO PLATINUM-BASED MEDICATIONS | 2005 |
|
RU2403065C2 |
| BISPECIFIC ANTI-HER2 / ANTI-HER3 ANTIBODIES | 2016 |
|
RU2653443C2 |
| METHOD FOR DETERMINING ANTIBODIES THAT INDUCE COMPLEMENT-DEPENDENT CYTOTOXICITY | 2015 |
|
RU2698205C2 |
| IMMUNOCYTOKINES BASED ON IL-15 AND IL-R[ALPHA] SUSHI DOMAIN | 2012 |
|
RU2644671C2 |
